Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

Overview of attention for article published in Frontiers in immunology, September 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 35,607 followers.

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients by Joanne E Davis https://t.co/ZNhbwb72n8

11 Oct 2021

Reply Repost Favourite

RT @FrontImmunol: New Research: Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechan…

24 Sep 2021

Reply Repost Favourite

New Research: Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients: Allogeneic stem cell transplantation (alloSCT) is utilised to cure… https://t.co/s2

24 Sep 2021

Reply Repost Favourite

Nice study just published from @Tsinghua_Uni masters student in lab using BCL2 and JAK1 inhibitors to reduce NK cells in combo with reduced irradiation dose as preconditioning for allo BM transplants with improved GVHD outcomes. Congrats Daisy, Jo et al 👏

24 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.